Latest News
Zafgen appoints Frances K. Heller to board
19 September 2014 - Biopharmaceutical company Zafgen (NasdaqGS :ZFGN) reported on Thursday that Frances K. Heller has been re-elected to its board of directors and member of the Audit Committee.

The company said its board currently includes eight directors, seven of whom are independent. From October 2011 to December 2013, Heller has served as the company director.

Most recently, Heller was a trustee and senior vice president of business development at Bristol-Myers Squibb. Currently, she is a trustee of the Dana Farber Cancer Institute. Previously, she was executive vice president of business development at Exelixis Pharmaceuticals and head of strategic alliances at Novartis Pharmaceuticals.

Login
Username:

Password: